Follow
Mohamed Alaa Gouda
Mohamed Alaa Gouda
Other namesMohamed Gouda
The University of Texas MD Anderson Cancer Center
Verified email at mdanderson.org - Homepage
Title
Cited by
Cited by
Year
Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
MA Gouda, V Subbiah
ESMO open 8 (2), 100788, 2023
302023
Tumor-agnostic precision medicine from the AACR GENIE database: clinical implications
MA Gouda, BE Nelson, L Buschhorn, A Wahida, V Subbiah
Clinical Cancer Research 29 (15), 2753-2760, 2023
272023
Medical Undergraduates' Contributions to Publication Output of World's Top Universities in 2013
MA Gouda, HS Zidan, AA Marey, MG Gameal, RG Elmahrook, A Saleh, ...
QJM, 2016
252016
Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors
MA Gouda, V Subbiah
American Society of Clinical Oncology Educational Book 43, e404770, 2023
222023
Family medicine in Egypt from medical students' perspective: a nationwide survey
MM AlKot, MA Gouda, MT KhalafAllah, MS Zahran, MM Kallaf, AM Zayed
Teaching and learning in medicine 27 (3), 264-273, 2015
202015
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers
MA Gouda, HJ Huang, SA Piha-Paul, SG Call, DD Karp, S Fu, A Naing, ...
JCO Precision Oncology 6, e2100512, 2022
172022
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate …
M Lapin, HJ Huang, S Chagani, M Javle, RT Shroff, S Pant, MA Gouda, ...
JCO Precision Oncology 6, e2100197, 2022
152022
N-of-1 Trials in Cancer Drug Development
MA Gouda, L Buschhorn, A Schneeweiss, A Wahida, V Subbiah
Cancer Discovery 13 (6), 1301-1309, 2023
122023
Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma
MA Gouda, J Polivka, HJ Huang, I Treskova, K Pivovarcikova, T Fikrle, ...
ESMO Open 7 (1), 100357, 2022
122022
Student research in arab world: what is the current state?
OA Aboshady, MA Gouda
Saudi medical journal 37 (6), 707, 2016
112016
Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer
FM Johnson, F Janku, MA Gouda, HT Tran, JD Kawedia, D Schmitz, ...
The Oncologist 27 (12), 1004-e926, 2022
92022
Ultrasensitive detection of BRAF V600E mutations in circulating tumor DNA of patients with metastatic thyroid cancer
MA Gouda, E Ong, HJ Huang, LW McPhaul, S Yoon, F Janku, ...
Endocrine 76 (2), 491-494, 2022
92022
Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
MA Gouda, V Subbiah
Therapeutic Advances in Medical Oncology 15, 17588359231177015, 2023
82023
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
MA Gouda, F Janku, A Wahida, L Buschhorn, A Schneeweiss, NA Karim, ...
Annals of Oncology, 2023
72023
ALK fusions in the pan-cancer setting: another tumor-agnostic target?
A Shreenivas, F Janku, MA Gouda, HZ Chen, B George, S Kato, ...
npj Precision Oncology 7 (1), 101, 2023
72023
Pros and cons of student journals
OA Aboshady, MA Gouda
Perspectives on Medical Education, 1-2, 2016
52016
Precision oncology for biliary tract tumors: it’s written in blood!
MA Gouda, V Subbiah
Annals of Oncology 33 (12), 1209-1211, 2022
42022
Pearls and pitfalls of ChatGPT in medical oncology
J Blum, AK Menta, X Zhao, VB Yang, MA Gouda, V Subbiah
Trends in Cancer, 2023
32023
529MO Activity, safety and circulating tumour DNA (ctDNA) dynamics of paradox breaker BRAF inhibitor PLX8394 in patients with advanced cancer
MA Gouda, EJ Sherman, GW Gilcrease, UN Vaishampayan, A Parikh, ...
Annals of Oncology 31, S465, 2020
32020
Mutation-agnostic detection of colorectal cancer using liquid biopsy-based methylation-specific signatures
MA Gouda, DY Duose, M Lapin, S Zalles, HJ Huang, Y Xi, X Zheng, ...
The oncologist 28 (4), 368-372, 2023
22023
The system can't perform the operation now. Try again later.
Articles 1–20